Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC

Towerview LLC lowered its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 70.6% during the third quarter, Holdings Channel reports. The firm owned 117,500 shares of the company’s stock after selling 282,500 shares during the quarter. Corvus Pharmaceuticals makes up about 0.4% of Towerview LLC’s portfolio, making the stock its 17th largest holding. Towerview LLC’s holdings in Corvus Pharmaceuticals were worth $620,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Samlyn Capital LLC increased its position in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after purchasing an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $10,855,000. Vanguard Group Inc. increased its position in Corvus Pharmaceuticals by 10.6% in the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after acquiring an additional 142,724 shares during the period. Marshall Wace LLP acquired a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $136,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $44,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CRVS shares. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Oppenheimer boosted their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, LADENBURG THALM/SH SH boosted their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.83.

Corvus Pharmaceuticals Trading Down 7.8 %

Shares of NASDAQ:CRVS traded down $0.69 during trading on Thursday, hitting $8.18. 305,525 shares of the stock were exchanged, compared to its average volume of 358,003. The company has a fifty day moving average price of $6.66 and a two-hundred day moving average price of $3.97. The company has a market cap of $511.66 million, a PE ratio of -8.66 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 12-month low of $1.30 and a 12-month high of $10.00.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.